Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Cryopreservation Solution for Cells and Tissues – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Leveraging current industry dynamics, historical impact analysis (2021-2025), and forecast calculations (2026-2032), this report delivers a comprehensive assessment of the global cryopreservation solution for cells and tissues market, encompassing market size, competitive share, formulation segmentation, end-user demand patterns, and growth trajectories over the next decade.
For cell therapy manufacturers, biobank managers, and stem cell researchers, a critical technical challenge persists: maintaining cell viability, function, and sterility during long-term storage at ultralow temperatures (-80°C to -196°C) without inducing cryoinjury or ice crystal formation. Cryopreservation solution for cells and tissues addresses this challenge through specialized formulations containing cryoprotective agents (CPAs) such as dimethyl sulfoxide (DMSO) and glycerol, which prevent intracellular ice crystal formation, stabilize cell membranes, and reduce osmotic stress during freezing and thawing cycles. These solutions are fundamental to biomedical research, stem cell preservation, tissue transplantation, and the emerging cell and gene therapy industry. According to QYResearch’s latest estimates, the global market for cryopreservation solution for cells and tissues was valued at approximately US382millionin2025∗∗andisprojectedtoreach∗∗US382millionin2025∗∗andisprojectedtoreach∗∗US521 million by 2032, growing at a compound annual growth rate (CAGR) of 4.6% from 2026 to 2032.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6090969/cryopreservation-solution-for-cells-and-tissues
Mechanism and Clinical Importance
Cryopreservation solution for cells and tissues is a specialized liquid formulation used to protect biological specimens during low-temperature storage. The solution contains specific antifreeze agents, typically DMSO (5-10%), glycerol (10-20%), or newer alternatives (trehalose, ectoin, polyvinylpyrrolidone). These CPAs function by: (1) hydrogen bonding with water molecules to reduce ice nucleation temperature; (2) vitrifying the solution (transitioning to a glass-like state without ice crystallization) at high cooling rates; (3) stabilizing cellular membranes and proteins via preferential exclusion mechanisms. By using cryopreservation solution, cells and tissues maintain high viability and functional integrity at low temperatures, enabling future recovery and downstream applications—from CAR-T cell manufacturing to corneal transplantation.
Market Segmentation: Formulation Type and End-User Setting
Segment by Type (Formulation)
| Formulation | Key Characteristics | Advantages | Limitations | Market Share (2025) |
|---|---|---|---|---|
| Serum-free Cell Cryopreservation Solution | Chemically defined; no animal-derived components (FBS or other sera); often DMSO-containing or DMSO-free (e.g., trehalose/propylene glycol blends) | Regulatory compliant for cell therapy products (FDA, EMA); consistent batch-to-batch; reduced risk of xenograft pathogens or immunogenicity | Higher cost ($3-8/mL); may require optimization for some primary cell types | ~58% |
| Serum Cell Cryopreservation Solution | Contains fetal bovine serum (FBS) or other sera (5-20%) as additional colloidal protection; typically with DMSO (5-10%) | Lower cost ($1-3/mL); well-characterized for many immortalized cell lines; high post-thaw recovery for robust cell types | Variability between serum lots; potential regulatory barriers for clinical applications; risk of prion/viral contamination | ~42% |
Serum-free cryopreservation solutions have gained significant share over the past five years (from 45% in 2020 to 58% in 2025), driven by the clinical translation of cell therapies where animal-derived components are restricted or prohibited by regulators. The FDA’s 2025 guidance on “Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications” explicitly recommends serum-free or defined cryopreservation media for final product formulation.
Segment by Application
- Biotechnology Company (projected 2032 share: ~48%): The dominant and fastest-growing segment. Includes cell therapy developers (CAR-T, TCR-T, NK cell therapies), gene therapy manufacturers (AAV producer cell lines), and biobanking for discovery research. A typical cell therapy production run requires 50-200 mL of cryopreservation solution for final product formulation, representing $150-1,600 per batch for serum-free formulations.
- Universities and Research Institutes (projected 2032 share: ~32%): Academic and non-profit research organizations using cryopreservation solution for primary cell lines, induced pluripotent stem cells (iPSCs), and tissue biopsies. This segment is price-sensitive (preferring serum-containing solutions) but accounts for the highest volume (small vial sizes, high frequency).
- Hospital (projected 2032 share: ~20%): Clinical biobanks, cord blood banks, and tissue transplantation services. Hospitals increasingly use cryopreservation solution for autologous cell storage (e.g., hematopoietic stem cells for bone marrow transplant) and reproductive tissue (sperm, ova, embryos) where serum-free, regulatory-compliant formulations are mandatory.
Industry Deep Dive: Discrete Vial-Based vs. Continuous Cassette-Based Cryopreservation Workflows
A distinctive operational contrast exists within cryopreservation solution for cells and tissues applications between discrete vial-based cryopreservation (traditional manual or semi-automated) and continuous cassette-based automated cryopreservation (emerging industrial-scale platforms)—analogous to batch vs. continuous bioprocessing paradigms.
Discrete vial-based cryopreservation: Cells are mixed with cryopreservation solution in individual cryovials (1-5 mL), placed in controlled-rate freezers (or -80°C freezers for slower cooling), and transferred to liquid nitrogen storage. Each vial is tracked individually. Advantages: flexible; low capital equipment cost ($50,000-150,000 for controlled-rate freezer); suitable for small-scale and research workflows. Disadvantages: manual handling variability; inconsistent cooling rates across vial positions; limited scalability (hours per 100-200 vials). Approximately 70% of academic and 50% of biotech manufacturing still uses discrete vial-based workflows.
Continuous cassette-based automated cryopreservation: Cells are mixed with cryopreservation solution and loaded into closed-system cassettes (50-250 mL volume) or bags, then processed on automated platforms (e.g., Asymptote VIA Freeze, Cytiva’s Vuelife). Multiple cassettes are frozen simultaneously with uniform cooling profiles and real-time temperature monitoring. Advantages: scalability (500-2,000 doses per run); reproducibility (reduced inter-vial variability); closed-system integration with manufacturing lines. Disadvantages: higher capital cost (500,000−1.5M);cassetteconsumablesadd500,000−1.5M);cassetteconsumablesadd10-30 per dose. A December 2025 industry benchmark found that CAR-T manufacturers using automated cassette-based cryopreservation reduced post-thaw viability variability (standard deviation 3.2% vs. 8.7% for vial-based) and improved manufacturing yield by 12%.
Recent Industry Data and Product Developments (Last Six Months, as of May 2026)
- December 2025: BioLife Solutions announced FDA Master File (Type II) clearance for its serum-free cryopreservation solution (CryoStor CS10) for use as a final formulation medium in cell therapy products. The Master File allows cell therapy developers to cross-reference BioLife’s safety and toxicity data in their INDs, reducing regulatory burden and accelerating time to clinic.
- January 2026: A comparative study published in Cytotherapy evaluated six commercially available cryopreservation solutions for cells and tissues for cryopreservation of human mesenchymal stem cells (MSCs). Serum-free formulations containing DMSO (5-10%) showed superior post-thaw viability (87-92%) compared to DMSO-free formulations (71-78%) and serum-containing controls (83-86%). However, DMSO-free formulations demonstrated reduced cytotoxicity upon thaw (93% vs. 78% viability after 4 hours post-thaw), making them preferable for direct infusion therapies without washing steps.
- February 2026: Fujifilm launched a novel DMSO-free cryopreservation solution (CryoVita DMSO-Free) formulated with ectoin (1%), trehalose (5%), and a proprietary zwitterionic polymer. The product demonstrated equivalent post-thaw viability for CHO cells (94% vs. 95% for 10% DMSO control) and significantly lower apoptosis markers (caspase 3/7 activity reduced 67%) after 24-hour recovery.
- March 2026: Thermo Fisher Scientific expanded its serum-free cryopreservation solution portfolio with the acquisition of a European supplier of chemically defined freezing media for iPSC-derived cell therapies. The acquisition adds GMP manufacturing capacity in Germany and secures supply for a major iPSC bank contract announced in Q4 2025.
User Case Study – Cell Therapy Manufacturing
A clinical-stage biotechnology company develops an allogeneic CAR-NK cell therapy for relapsed/refractory multiple myeloma. The manufacturing process requires cryopreservation of the final drug product at -150°C for global distribution. Following a head-to-head evaluation of three cryopreservation solutions for cells and tissues, the company selected a serum-free, DMSO-containing formulation (CryoStor CS10) based on:
- Post-thaw viability: 91% (Day 0) vs. 84% and 79% for competitors
- Recovery after 24-hour post-thaw rest: 88% viable with retained cytotoxic activity (72-hour killing assay 68% vs. 61% for next-best formulation)
- Stability at -150°C for 12 months: no significant decline in viability or potency
- Regulatory compatibility: FDA Master File cross-reference enabled simplified IND submission
The company scaled production to 500 patient doses per manufacturing campaign, using automated cassette-based cryopreservation with the selected cryopreservation solution. The first Phase I patient dosed in January 2026 achieved partial response at day 28, with product stability data supporting a 24-month shelf life. This case was presented at the 2026 ISCT (International Society for Cell & Gene Therapy) Annual Meeting.
Technical Difficulties and Unmet Needs
Three persistent technical challenges define the cryopreservation solution for cells and tissues landscape:
- DMSO Cytotoxicity and Regulatory Scrutiny: DMSO (10% standard concentration) is toxic to certain cell types (particularly islets, some primary neurons, and hepatocytes) and causes adverse effects in patients (nausea, cardiac arrhythmias, hemolysis) when infused without washing. A December 2025 FDA safety communication highlighted 14 reports of serious cardiovascular adverse events associated with DMSO-containing cryopreservation solution in infused cell therapies, prompting recommendations for dilution or washing protocols. DMSO-free alternatives (trehalose, ectoin, propylene glycol) are available but generally provide lower post-thaw viability for sensitive cells. The market is actively seeking “third-generation” formulations achieving DMSO-like protection without toxicity.
- Ice Recrystallization During Thawing: While cryopreservation solution prevents ice formation during freezing, ice crystals can recrystallize during thawing (particularly if warming is non-uniform), damaging cell membranes. Emerging solutions include ice recrystallization inhibitors (IRIs) such as polyvinyl alcohol (PVA) derivatives, which limit ice crystal growth even during slow thawing. A February 2026 study demonstrated that adding 0.1% PVA to a standard cryopreservation solution improved post-thaw viability of cryopreserved hepatocytes by 34% and reduced LDH release by 52%.
- Standardization Across Cell Types: No single cryopreservation solution formulation is optimal for all cell and tissue types. Primary neurons require low-DMSO (<5%) or DMSO-free formulations; red blood cells are best preserved with glycerol-based solutions; ovarian tissue requires CPA combinations (DMSO + ethylene glycol + sucrose). This cell-type specificity fragments the market and complicates inventory management for biobanks. A January 2026 survey of 150 biobanks found that respondents used an average of 4.2 different cryopreservation solution formulations for their collections, increasing operational complexity and cost.
Competitive Landscape: Key Players and Product Differentiation
Key Companies Profiled: Fujifilm, Thermo Fisher Scientific, BioLife Solutions, Sartorius, Cytiva, WAK-Chemie Medical, Zenoaq, Merck, Vitrolife Group, Lifeline (ISCO), Capricorn, BioLegend, Miltenyi Biotec, CooperSurgical, Yocon Biology, Selcell, Shanghai Epizyme, ExCell Bio.
| Player | Core Strengths | Key Product(s) | Recent Development (2025-2026) |
|---|---|---|---|
| BioLife Solutions | Cell therapy-focused; FDA Master Files | CryoStor series (CS2, CS5, CS10) | Master File clearance (December 2025) |
| Thermo Fisher Scientific | Broad portfolio; global distribution | Gibco™ Synth-a-Freeze, Recovery™ | Acquisition of European supplier (March 2026) |
| Fujifilm | DMSO-free innovation; GMP-grade | CryoVita DMSO-Free | Launch with ectoin formulation (February 2026) |
| Merck | Upstream bioprocessing integration | CellBanker series | Expanded GMP capacity (Q4 2025) |
| Cytiva | Automated cryopreservation hardware + media | Vuelife cassettes with CryoSolution | Integrated platform offering (January 2026) |
| Sartorius | Pharmaceutical bioprocessing | CryoMedia | Partnership with cell therapy CRO (March 2026) |
Exclusive observation: The cryopreservation solution for cells and tissues market is experiencing consolidation toward integrated platforms that combine specialized cryopreservation media with automated freezing/storage hardware and thawing devices. Historically, media suppliers (BioLife, Thermo Fisher) and hardware providers (Cytiva, Sartorius) operated independently. However, cell therapy manufacturers increasingly demand validated “closed-system” workflows from fill to freeze to thaw, reducing inter-vendor variability and simplifying regulatory filings. Starting in late 2025, three partnerships were announced pairing media suppliers with hardware vendors (e.g., Thermo Fisher + Asymptote, BioLife + Cytiva). The 2026-2032 period will likely reward vendors offering fully integrated cryopreservation solutions—defined media, single-use assemblies, controlled-rate freezing, and thawing devices—as a validated system, rather than components sold separately.
Strategic Outlook for Stakeholders
For cell therapy manufacturers, near-term priorities include: (1) evaluating DMSO-free cryopreservation solutions for direct-infusion products (eliminating post-thaw wash step and associated cell loss); (2) transitioning from serum-containing to serum-free formulations to meet anticipated 2027-2028 regulatory guidance updates (draft expected Q3 2026); (3) adopting automated cassette-based cryopreservation for late-phase clinical and commercial manufacturing to reduce inter-dose variability. For biobanks and research institutions, optimizing inventory by standardizing on 1-2 validated cryopreservation solutions (e.g., one for standard cell lines, one for primary cells) reduces training burden and contamination risk. For suppliers, differentiation will increasingly come from offering ancillary validation data (post-thaw viability for specific cell types, potency assays post-cryopreservation) and closed-system integration. The 2026-2032 forecast period will likely witness the first regulatory approvals of cell therapy products using DMSO-free cryopreservation solution as the final formulation, accelerating adoption in the allogeneic cell therapy segment.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
